Releaf – Project Twenty21

Project Twenty21 Australia is an observational study where data is being collected from Australian patients who have been prescribed medicinal cannabis products through Releaf Clinics for one of four main conditions: chronic pain, anxiety, PTSD or MS. Project Twenty21 Australia is a collaboration between The Australasian College of Cannabinoid Medicine (also known as ACCM) and the Drug Science, a UK-based organisation. Project Twenty21 Australia is the Australian arm of this project, where data will be collected from an Australian population using medicinal cannabis at Releaf Clinics.

Levin Health is one of five brands to participate in this study.

Participants Cohort

Recruitment for the over 1,000 patients started in February 2022. Several Releaf Clinic clinicians are involved in the study.

Medication

Patients eligible for the study may be prescribed from a project formulary containing cannabis flower and medicinal cannabis oil products from five different companies. Medicinal cannabis oil products contain various combinations and strengths of CBD and/or THC. The prescribing doctor will choose a product or products they consider most suitable for the patient’s condition. 

Data Analysis

The study will study the impact of medicinal cannabis on four clinical conditions:

  • Multiple Sclerosis (MS) 
  • Chronic Pain (CP)
  • Anxiety
  • Post-traumatic stress disorder (PTSD)

Levin Health products may be selected from the formulary by doctors for patients presenting with any of these four conditions. 

Findings

Project Twenty21 Australia will seek to investigate whether the products on the formulary are efficacious in alleviating symptoms associated with chronic pain, anxiety, PTSD and MS, as well as improving quality of life, sleep, depression/mood. The study will also assess the perceived impact of treatment and the safety of medicinal cannabis products.

Disclaimer: This study involves medicinal cannabis products which are not registered on the Australian Register for Therapeutic Goods (ARTG) and can only be accessed via the Special Access Scheme (SAS, category A or B) or the Authorised Prescriber scheme. The prescription of any unregistered product is at the discretion of the prescribing physician.